CN1055235C - Oral liquor for treatment of lung cancer and preparation method therefor - Google Patents

Oral liquor for treatment of lung cancer and preparation method therefor Download PDF

Info

Publication number
CN1055235C
CN1055235C CN97101000A CN97101000A CN1055235C CN 1055235 C CN1055235 C CN 1055235C CN 97101000 A CN97101000 A CN 97101000A CN 97101000 A CN97101000 A CN 97101000A CN 1055235 C CN1055235 C CN 1055235C
Authority
CN
China
Prior art keywords
radix
herba
treatment
oral liquid
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97101000A
Other languages
Chinese (zh)
Other versions
CN1192910A (en
Inventor
鲍广海
张嘉林
王德春
Original Assignee
鲍广海
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鲍广海 filed Critical 鲍广海
Priority to CN97101000A priority Critical patent/CN1055235C/en
Publication of CN1192910A publication Critical patent/CN1192910A/en
Application granted granted Critical
Publication of CN1055235C publication Critical patent/CN1055235C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a pure traditional Chinese medicinal oral liquid for curing pulmonary cancers and a preparation method thereof. The oral liquid of the present invention is prepared from 14 traditional Chinese medicines, and is prepared by using the modern scientific method, being combined with the traditional preparation experience and extracting the effective ingredients. Proved by the clinical application of years, the oral liquid of the present invention provides an ideal anticancer medicine with obvious curative effects and the functions of promoting blood circulation for removing blood stasis, clearing heat and toxic materials, removing obstruction, relieving pains, removing the necrotic tissue, promoting granulation, strengthening immunity and relieving symptoms for patients with intermediate and late pulmonary cancers and not suitable for operations or radiotherapy and chemotherapy.

Description

Treatment pulmonary carcinoma oral liquid and preparation method thereof
The invention belongs to Chinese medicine preparation, a kind of oral liquid that is used for the treatment of pulmonary carcinoma and preparation method thereof.
At present, the treatment method for cancer is a lot of both at home and abroad, the main means such as operation, radiotherapy or chemotherapy that adopt, but put, in the process of chemotherapy, the healthy cell of human body and immune system also are subjected to injury in various degree simultaneously, this is difficult to bear for a cancer patient that has a delicate constitution, especially to one lost surgical engine can in, end-stage patients are willing and yet unable to help especially, expect earnestly a kind of enhancing human body immunity power can be arranged, cancer therapy drug comes out early safely and effectively.
The objective of the invention is to propose a kind of be in, be not suitable for operating late period or carry out the lung cancer patient of radiotherapy, chemotherapy, a kind of relief of symptoms be provided, prolong life, safe and reliable, taking convenience, curative effect be obvious, total effective rate can reach the desirable curing cancer drug more than 90%, treatment pulmonary carcinoma oral liquid.
Major technique content of the present invention is that this treatment pulmonary carcinoma oral liquid prescription and weight proportion are: Herba Agrimoniae 20~25%, Herba Hedyotidis Diffusae 10~15%, Herba Scutellariae Barbatae 10~12%, Radix Scutellariae 6~8%, the Radix Astragali 6~8%, Radix Sophorae Flavescentis 5~6%, Radix Salviae Miltiorrhizae 5~6.5%, Herba Taraxaci 4~5%, Radix Adenophorae (Radix Glehniae) 4.5~5.5%, Radix Ophiopogonis 4.5~5.5%, the Rhizoma Atractylodis Macrocephalae 5~6%, Herba Lobeliae Chinensis 4~5%, Radix Glycyrrhizae 3~3.5%, Fructus Ligustri Lucidi 3~3.5%.
The preparation method of described pulmonary carcinoma oral liquid is with Herba Agrimoniae, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Radix Scutellariae, the Radix Astragali, Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae, Herba Taraxaci, Radix Adenophorae (Radix Glehniae), Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Herba Lobeliae Chinensis, Radix Glycyrrhizae, 14 flavor Chinese medicines such as Fructus Ligustri Lucidi add water to the medicine submergence, decoct secondary, decocted 2~2.5 hours for the first time, decocted 1~1.5 hour for the second time, filter the back merging filtrate respectively, concentrate, left standstill 24 hours, get its supernatant, add the sucrose reheat dissolving of medicinal liquid total amount 20~30%, the cooling back adds distilled water 2 times to prepared slices of Chinese crude drugs total amount, stirs evenly, liquid after the filtration is treatment pulmonary carcinoma oral liquid, and packing gets final product.
The present invention is in excavating motherland's pools of traditional Chinese medicine, in conjunction with clinical experience for many years, use modern science and technology Chinese medicines such as Chinese medicine Herba Agrimoniae, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae, Radix Adenophorae (Radix Glehniae), the Radix Astragali, Radix Scutellariae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Herba Taraxaci, Radix Glycyrrhizae, Fructus Ligustri Lucidi, Herba Lobeliae Chinensis are processed into oral liquid through screening, the process of preparing Chinese medicine.Herba Agrimoniae has astringing to arrest bleeding; Radix Astragali energy granulation promoting poison holding, the Radix Salviae Miltiorrhizae promoting blood circulation to remove obstruction in the collateral; The Radix Glycyrrhizae QI invigorating and in; Radix Ophiopogonis, Radix Adenophorae (Radix Glehniae) energy moistening the lung and resolving phlegm, nourishing YIN and clearing away heat; Herba Lobeliae Chinensis, Herba Scutellariae Barbatae, Herba Taraxaci, Radix Scutellariae, Radix Sophorae Flavescentis have heat-clearing and toxic substances removing, reducing swelling and alleviating pain, effects such as blood circulation promoting and blood stasis dispelling; Fructus Ligustri Lucidi, Rhizoma Atractylodis Macrocephalae energy invigorating QI to consolidate the body surface resistance, enhancing human body immunity function, right supporting anticancer; Herba Hedyotidis Diffusae has inhibitory action to cancer and can form by enhancing antibody, improves leukocytic phagocytic activity.More than each medicine compatibility make oral liquid.Therefore this medical instrument blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, removing obstruction for relieving pain arranged, remove the rotten and let fresh grow, immune cell activated, improve immunologic function, promote the nutrition rehabilitation of the The Nomenclature Composition and Structure of Complexes of tissue and cell, the enhancing body resistance against diseases, kill the carcinoma cell, the tumor body is dwindled, alleviate and alleviate clinical symptoms, improve patient's life quality, thereby prolong patient's life.
Embodiments of the invention:
Get Herba Agrimoniae 200g, Herba Hedyotidis Diffusae 130g, Herba Scutellariae Barbatae 120g, Radix Scutellariae 80g, Radix Astragali 80g, Radix Sophorae Flavescentis 50g, Radix Salviae Miltiorrhizae 30g, Herba Taraxaci 45g, Radix Adenophorae (Radix Glehniae) 45g, Radix Ophiopogonis 50g, Rhizoma Atractylodis Macrocephalae 50g, Herba Lobeliae Chinensis 40g, Radix Glycyrrhizae 30g, Fructus Ligustri Lucidi 30g, decoct with water secondary, it is 2 hours for the first time, it is 1 hour for the second time, after filtering respectively, merging filtrate, after concentrating, leave standstill and got supernatant adding 500g sucrose in 24 hours, heating for dissolving, cooling back adding distil water stirs evenly filtration to 2000ml, and liquid subpackage is got final product.
Instructions of taking: every day three times, each 40ml (heating before the clothes) taking medicine before meal is used.
The present invention is without any side effects through zoopery and clinical use, and effect is remarkable.From January nineteen ninety-five~1997 year January to 192 examples in, the short term effect of advanced lung cancer is obvious.Clinical sign and clinical symptom remission rate are 87.5%, and the focus minification is 45.4%, and 1 year person of survival period is 94.1%, and be more obvious to improving patient's quality of life and prolonging life cycle.Through clinical observation, definite diagnosis before the treatment is a foundation with lonizing radiation (X line, CT) endoscope, surgery Pathology (human cytology) check etc., to this group patient's treatment, its drug dose is 40ml, day clothes three times, ante cibum is oral, continuous use was a course of treatment in one month, had a rest a week, continued course of treatment of medication then, be a total course of treatment three courses of treatment, also can take throughout one's life.Observation before and after the patient treatment, write up symptom, sign change, binding of pathological is learned and checked simultaneously: actinology (X line, CT), conventional urine, blood sample test, liver, renal function check etc. finish the back and follow up a case by regular visits to once every half a year as foundation total course of treatment.
Observe as follows with reference to " pulmonary carcinoma efficacy assessment standard " to 192 routine medium and advanced lung cancer short term effects:
Produce effects: partly alleviating (PR) focus dwindles>and 50%, clinical symptoms is obviously improved.
Effectively: slightly alleviating (MR) focus dwindles<and 50%, clinical symptoms makes moderate progress.
Invalid: do not have alleviating (PD) focus does not have and dwindles or increase to some extent, and clinical symptoms increases the weight of.
The male is 129 examples in 192 examples, women's 63 examples, and men and women's ratio is 2: 1.Age reckling 16 years old, the oldest person 79 years old, the mean age is 56.2 years old.50-60 year, age group amounted to 69 examples, and accounting for this group 35.9% is age bracket occurred frequently.Age bracket amounted to 39 examples and accounted for this group 21% 40-50 year.Centre type 149 examples, peripheral type 43 examples.Focus is positioned in the right lung, and the person is 123 examples, and left lung person is 68 examples, and two lung persons are 1 example only.Above-mentioned case is medium and advanced lung cancer (all have in various degree and shift).
Sign and observation of symptoms: this organize 192 routine patients take this Drug therapy after total course of treatment observed result be that cough, uncomfortable, uncomfortable in chest, chest pain etc. all have clear improvement, even disappearance.Expectoration, sputum mixed with blood, heart beating are breathed hard, slight fever also has alleviation, so the alleviation degree of sign and symptom is 87.5%, see table 1 for details.
Sign and symptom variation before and after the table 1 192 routine medium and advanced lung cancer treatments
Sign, symptom The example number Obviously alleviate The slight alleviation Invalid Remission rate %
Cough 192 65 107 20 89.6
Expectoration 45 30 26 9 86.2
Become thin 189 25 139 25 86.8
Anorexia 179 32 132 15 91.6
Hemoptysis expectorant 63 15 36 12 80.9
Chest pain 190 35 139 16 91.6
Uncomfortable in chest 177 39 122 16 90.0
Slight fever 93 39 40 14 84.8
The heart beating of breathing hard 105 15 76 14 86.7
Weak 182 39 119 24 86.8
Annotate: patient one people is simultaneously with multiple sign symptom, classified counting during statistics during statistics.
Result before and after lonizing radiation (X line, CT) contrast is taken medicine, after 192 routine medium and advanced lung cancer patients use the total end course of treatment of this medicine, observing the preceding pulmonary lesions minification of treatment is 45.4%, pulmonary lesions dwindles>50% (comprising 50%) above person be 7.2%, pulmonary lesions dwindles<and 50% be 35.1%, be considerable so use behind this medicine to the pulmonary lesions curative effect.See table 2 for details.
Table 2 medium and advanced lung cancer treatment back pulmonary lesions dwindles observation
Typing The example number Pulmonary lesions dwindles degree
>1/2 <1/2 No change Minification %
Centre type 149 11 48 90 39.6
Peripheral type 43 5 17 21 51.2
Add up to 192 16 65 111 45.4
Annotate: have an example only to make case statistics for the bilateral person in the statistics, this example is a centre type.
Quality of life observes: after this group patient used this Drug therapy, variation had taken place in integral body, and especially the raising of patient quality of life is more considerable, to patient live bring happy.The life person that fully not can take care of oneself is that 15 examples account for this group 7.8% before the treatment, can not self-care person be 119 examples fully, accounts for this group 62%; Life person's 114 examples that fully not can take care of oneself account for this group 59.4% after this Drug therapy, rise 51.6%, and life fully self-care person be 21 examples, account for this group 10.9%, decline 51.1% sees table 3 for details.
The life quality of observing the patient is very important, but observes the valuable index that also be this curative effect of medication of explanation its life cycle.192 routine patients are after medication, can the communication contact person totally 102, the year and a day person that now survives has 96, account among the person of following up a case by regular visits to 94.1%, the life cycle of medium and advanced lung cancer is than short, though previously all produce little effect through multiple treatment measure, and with behind this medicine, patient's the annual phase of depositing is significantly improved, so this medicine is a desirable evidence to current medium and advanced lung cancer patient.
The observation of quality of life before and after the treatment of table 3 medium and advanced lung cancer
The treatment situation Life is taken care of oneself fully Life partial self-help Can't take care of oneself at all
The example number Percentage ratio The example number Percentage ratio The example number Percentage ratio
Before the treatment 15 7.8 58 30.2 119 62
After the treatment 114 59.4 57 29.7 21 10.9
Show from the observation of curative effect of this research, take this medicine medium and advanced lung cancer is had uniqueness and obvious curative effects, sign and clinical symptoms all have positive effect, its total effective rate is 87.5%, through lonizing radiation checks (X line, CT), the pulmonary lesions minification is 45.4%, and patient's fuselage state obviously improves, quality of life improves constantly, and 1 year its life cycle, the person was unexpectedly up to 94.1%.This group patient is the middle and advanced stage patient, and end-stage patients promptly can not perform the operation, and most of patient can not accept radiation and chemotherapy, so patient's life cycle is shorter, current phase patient's treatment has become difficulty to this.And can improve sings and symptoms after using this medicine, and can improve the quality of life again, prolong life cycle, most of patient's clinical symptoms all takes an evident turn for the better simultaneously, pulmonary lesions dwindles, and patient has not only treated pulmonary carcinoma after taking this medicine, and also effective in cure to other complication, complication.Because this medicine can improve patient's autoimmunity, so that this medicine and operation, radiotherapy, chemotherapy combined are used its curative effect is better.
By animal experiment and clinical observation, this medical instrument has the division that suppresses tumor cell, even killing action is arranged, thereby growth of tumor is controlled.
These medicine characteristics; Nontoxic, side effect, be safer, reliable, efficient, without the anticancer good medicine of contraindication.
The curative effect of this medicine can provide the use testimonial material of related hospitals.

Claims (2)

1, a kind of oral liquid for the treatment of pulmonary carcinoma, it is characterized in that: this oral liquid is made up of following raw materials according, and its weight proportion is: Herba Agrimoniae 20-25%, Herba Hedyotidis Diffusae 10-15%, Herba Scutellariae Barbatae 10-12%, Radix Scutellariae 6-8%, Radix Astragali 6-8%, Radix Sophorae Flavescentis 5-6%, Radix Salviae Miltiorrhizae 5-6.5%, Herba Taraxaci 4-5%, Radix Adenophorae (Radix Glehniae) 4.5-5.5%, Radix Ophiopogonis, 4.5-5.5%, Rhizoma Atractylodis Macrocephalae 5-6%, Herba Lobeliae Chinensis 4-5%, Radix Glycyrrhizae 3-3.5%, Fructus Ligustri Lucidi 3-3.5% formed.
2, the oral liquid compounding method of treatment pulmonary carcinoma according to claim 1 is characterized in that: 14 flavor Chinese medicines are added water to the medicine submergence, decoct secondary, decocted 2-2.5 hour for the first time, second decocted 1-1.5 hour, filtered the back merging filtrate respectively, concentrated, left standstill 24 hours, get its supernatant, add the sucrose of amount of liquid medicine 20-30%, heating for dissolving, the cooling back adds distilled water 2 times to prepared slices of Chinese crude drugs total amount, stirs evenly the filtration packing and gets final product.
CN97101000A 1997-03-12 1997-03-12 Oral liquor for treatment of lung cancer and preparation method therefor Expired - Fee Related CN1055235C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN97101000A CN1055235C (en) 1997-03-12 1997-03-12 Oral liquor for treatment of lung cancer and preparation method therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN97101000A CN1055235C (en) 1997-03-12 1997-03-12 Oral liquor for treatment of lung cancer and preparation method therefor

Publications (2)

Publication Number Publication Date
CN1192910A CN1192910A (en) 1998-09-16
CN1055235C true CN1055235C (en) 2000-08-09

Family

ID=5165463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97101000A Expired - Fee Related CN1055235C (en) 1997-03-12 1997-03-12 Oral liquor for treatment of lung cancer and preparation method therefor

Country Status (1)

Country Link
CN (1) CN1055235C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011559B (en) * 2007-02-01 2011-06-01 南中兴 Traditional Chinese medicine preparation for treating malignant tumor and its preparation method
CN101612251B (en) * 2009-07-27 2011-08-31 沈信堂 Traditional Chinese medicine for treating primary liver cancer
CN108355014A (en) * 2018-05-23 2018-08-03 北京雄九医学研究院 Anticancer traditional Chinese medicinal composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《山东中医杂志》11(1) 1992.1.1 马廷行等,滋阴清热解毒法治疗肺癌240例疗效比较 *

Also Published As

Publication number Publication date
CN1192910A (en) 1998-09-16

Similar Documents

Publication Publication Date Title
CN103041317B (en) A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof
CN101195008A (en) Cattail pollen skin cleaning agent for treating gynecology disease and technique of preparing the same thereof
CN100457158C (en) Medicine for fortifying human body immune function
CN102210820A (en) Chinese medicinal composition for treating leukemia
CN101234181B (en) Medicament for preventing and treating leukopenia used in tumor radiotherapy and chemotherapy course
CN1150928C (en) Medicine for curing cancers and its preparation method
CN1305515C (en) Chinese medicinal powder and decoction composition for treating cancer
CN101317965B (en) Traditional Chinese medicinal preparation for treating cancer
CN101306138B (en) Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method
CN1055235C (en) Oral liquor for treatment of lung cancer and preparation method therefor
CN100386106C (en) Medicine for treating acne and its preparation
CN1173726C (en) Medicine for curing malignant turnor and its preparation method
CN1294961C (en) Oral liquid for curing myocardial ischemia and process for preparing the same
CN115089663B (en) Traditional Chinese medicine composition with qi-tonifying and body fluid-generating effects and preparation method thereof
CN1127968C (en) Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method
CN1186060C (en) Chinese medicine capsule and adhesive plaster for treating mammary cancer and its preparation method
CN116350731B (en) Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof
CN102580053B (en) Traditional Chinese medicine formulation for preventing and treating cancer
CN112206279B (en) Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof
CN101396454B (en) Traditional Chinese medicine for treating diabetic skin pruritus
CN1325105C (en) Oral liquid for clearing liver and gallbladder
CN1413657A (en) Chinese medicine capsule, pill for treating liver cancer and preparation method
CN111388564A (en) Traditional Chinese medicine for treating bradyarrhythmia
CN114617934A (en) Detoxifying and whitening soup
CN1065754C (en) Chinese patent medicine for treating cancer leucocyte and blood platelet reduction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee